Patents by Inventor Yoram Devary

Yoram Devary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12071488
    Abstract: A combinational therapy for treatment of cancer. Compositions, methods and kits for treatment of cancer and for sensitizing cancer cells to a broad spectrum of anti-cancer agents.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: August 27, 2024
    Assignee: TWO TO BIOTECH LTD.
    Inventor: Yoram Devary
  • Patent number: 11813305
    Abstract: Provided are methods, agents and kits for use in assessing the effect of treatment on cancer patients. Further provided is a combination therapy for reducing the administered standard of care doses of anti-cancer agents in treated cancer patients.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: November 14, 2023
    Assignee: IMMUNE SYSTEM KEY LTD.
    Inventors: Yoram Devary, Uziel Sandler
  • Patent number: 10933117
    Abstract: Provided are methods, agents and kits for use in assessing the effect of treatment on cancer patients. Further provided is a combination therapy for reducing the administered standard of care doses of anti-cancer agents in treated cancer patients.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 2, 2021
    Assignee: IMMUNE SYSTEM KEY LTD.
    Inventors: Yoram Devary, Uziel Sandler
  • Patent number: 9878015
    Abstract: The invention provides isolated peptides, fragments and derivatives thereof and pharmaceutical compositions comprising same that are useful for the prevention or treatment of cancer metastasis.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: January 30, 2018
    Assignee: IMMUNE SYSTEM KEY LTD.
    Inventors: Yoram Devary, Uziel Sandler
  • Patent number: 8071716
    Abstract: The invention provides the novel thymus-specific human protein T101, an 84-amino acid polypeptide isolated from the human thymus. The full T101 peptide contains a 33-amino acid signal peptide and a 51-amino acid T101 peptide sequence with both immune stimulatory and inhibitory activities. Also provided are modified peptides and partial T101 peptide sequences.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: December 6, 2011
    Assignee: Immune System Key Ltd.
    Inventors: Yoram Devary, Uziel Sandler
  • Publication number: 20100204097
    Abstract: A method for treating or preventing a disease involving a cell having a T1/ST2 receptor, including administering to subject in need thereof a therapeutically effective amount of a thymic peptide, is provided. Also provided is a method for inhibiting the pathological effects of activated monocytes in a subject in need thereof including treating the monocytes with an effective amount of the thymic peptide.
    Type: Application
    Filed: December 18, 2007
    Publication date: August 12, 2010
    Applicant: IMMUNE SYSTEM KEY LTD.
    Inventors: Yoram Devary, Uziel Sandler
  • Publication number: 20090018060
    Abstract: The invention provides the novel thymus-specific human protein T101, an 84-amino acid polypeptide isolated from the human thymus. The full T101 peptide contains a 33-amino acid signal peptide and a 51-amino acid T101 peptide sequence with both immune stimulatory and inhibitory activities. Also provided are modified peptides and partial T101 peptide sequences.
    Type: Application
    Filed: October 26, 2005
    Publication date: January 15, 2009
    Applicant: IMMUNE SYSTEM KEY LTD.
    Inventors: Yoram Devary, Uziel Sandler